Skip to content

Effectiveness evaluation of remote management of lupus erythematosus compared with traditional treatment, a multicenter, randomized controlled trial

Effectiveness evaluation of remote management of lupus erythematosus compared with traditional treatment, a multicenter, randomized controlled trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100052775
Enrollment
Unknown
Registered
2021-11-05
Start date
2021-11-15
Completion date
Unknown
Last updated
2022-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lupus erythematosus

Interventions

Traditional treatment group:Outpatient follow-up
Remote management group:Online follow-up

Sponsors

Institute of Dermatology, Chinese Academy of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 88 Years

Inclusion criteria

Inclusion criteria: 1. Aged >=18 years, patients diagnosed with systemic lupus erythematosus (SLE) who meet the 2019 EULAR/ACR SLE classification criteria; 2. Aged >=18 years, refer to the guidelines for the diagnosis and treatment of cutaneous lupus erythematosus (2019 edition) formulated by the Lupus Erythematosus Research Center of the Dermatology and Venereology Branch of the Chinese Medical Association, patients with clinically diagnosed cutaneous lupus erythematosus (CLE) who do not meet the 2019 EULAR/ACR SLE classification criteria; 3. Those who signed the informed consent, voluntarily accepted the treatment and were able to complete the follow-up as required.

Exclusion criteria

Exclusion criteria: 1. Associated with chronic infectious diseases (such as hepatitis B, tuberculosis, etc.), tumors, other connective tissue diseases other than lupus erythematosus, and diseases of various systems that seriously affect the quality of life of patients (except well-controlled hypertension and diabetes); 2. There are neurological, mental diseases or physical disorders (such as deafness and dumbness) that may affect the normal treatment and follow-up cooperation of patients, or in the severe active period of neurological lupus, lupus crisis and other diseases (Inclusion can be resumed after the critical period and stable condition).

Design outcomes

Primary

MeasureTime frame
Visual analogue scale of disease severity self-assessment;Visual analogue scale of medical service quality survey;Treatment satisfaction questionnaire for medication;Treatment compliance;Quality of life;Emotional assessment;Adverse event;

Countries

China

Contacts

Public ContactLu Qianjin

Institute of Dermatology, Chinese Academy of Medical Sciences

qianlu5860@gmail.com+86 25 85478078

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026